On June 25, 2018, Bio-Techne announced it is acquiring Exosome Diagnostics for $250 million in cash and up to $325 million for achieving certain milestones. As exosome therapeutics and diagnostics have multiplied in number, a number of investors have placed big bets on this rapidly growing marketplace.
Exosomes are small vesicles ranging from 30-100nm in size that are secreted by nearly all cell types. They facilitate a range of important cellular functions, including facilitating intercellular communication.
Bio-Techne Acquires Exosomes Diagnostics
According to Charles R. Kummeth, President and CEO of Bio-Techne, “ExosomeDx’s technology is a game changer, and positions Bio-Techne to be a leader in the rapidly-growing non-invasive liquid biopsy market. There are multiple synergies with our core company, including our 40-year track record of developing and commercializing the highest-quality biologicals, especially in the field of cytokines.”
With Exosome Diagnostics controlling approximately 200 filed patents and applications pertaining to exosome-based diagnostics, Bio-Techne is betting the deal will position it as a leader in the rapidly growing non-invasive liquid biopsy market.
Previously, Exosome Diagnostics raised $80 million in its Series A and Series B rounds, which it followed with $30 million in its Series C round.
There have also been a number of other important funding events within the exosome sector. Codiak Biosciences was formed in 2016 when the University of Texas MD Anderson Cancer Center joined two venture capital firms (ARCH Venture Partners and Flagship Ventures) to launch the company.
Codiak raised $31 million in a Series A round, $61 million in Series B round, and $76.5 million in Series C round, bringing its total to $168.5 million.
In May 2017, ExCoBio, Inc. raised US $11 million in a Series A round within months of being founded, making it the “largest and fastest investment attraction in South Korea.” In aggregate, ExoCoBio raised US $13.5 million and is planning to establish R&D and GMP facilities to commercialize exosome-based cosmeceuticals and biopharmaceuticals.
In total, funding into exosome companies has exceeded a half a billion dollars and the investments are accelerating.
Exosome Market Report
Would you benefit from knowing all exosome investments worldwide, including financing rounds, acquisitions, and partnerships? The 134-page global strategic report the “Market for Stem Cell Exosomes” reviews all aspects of the exosome marketplace, including market size, segments, opportunities, and threats.
It also presents “hotspots” for exosome market activity and leading competitors driving innovative within the marketplace.